Kura Oncology Reports Q3 Revenue Growth for Komzitfi and Outlines Future Clinical Milestones
Kura Oncology reported significant growth in its third quarter, driven by the performance of KOMZIFTI. The drug's net product revenue reached $13.9 million, representing a 53% sequential increase, while new patient starts rose by 30%. CEO Troy Wilson noted that the company has maintained a majority share within the menin inhibitor market. Looking ahead, Kura outlined its strategic funding and clinical roadmap, including up to $300 million in Oberland funding. The company also plans to initiate a registrational study for darlifarnib involving approximately 40 patients, which is targeted to begin in the first half of 2027.
Tickers: $KURA
Topics: menin inhibitor patient acquisition product revenue quarterly earnings
Read the full article at Seeking Alpha
Part of the story Kura Oncology Reports Q3 2026 Results with Strong KOMZIFTI Revenue Growth (13 articles)